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Summary
We developed a rodent model that mimics the osteoblastic and osteolytic changes associated with human metastatic
prostate cancer. Microarray analysis identified MMP-7, cathepsin-K, and apolipoprotein D as being upregulated at the
tumor-bone interface. MMP-7, which was produced by osteoclasts at the tumor-bone interface, was capable of processing
RANKL to a soluble form that promoted osteoclast activation. MMP-7-deficient mice demonstrated reduced prostate
tumor-induced osteolysis and RANKL processing. This study suggests that inhibition of MMP-7 will have therapeutic
benefit in the treatment of prostate cancer-induced osteolysis.S I G N I F I C A N C E
Understanding how metastatic prostate cancer cells induce changes in bone matrix homeostasis is essential for the identification
of new therapies to control metastatic disease. Here, we describe an in vivo model that accurately recapitulates the behavior of
human metastatic prostate cancer in the bone environment by developing mixed osteoblastic and osteolytic lesions. Using this
model, we identified the expression of MMP-7 at the tumor-bone interface and demonstrated a molecular mechanism by which
MMP-7 can mediate osteolysis. Our study contributes to the growing consensus for the use of MMP inhibitors for the treatment of
pathological bone disease.Introduction
In the United States alone, 29,900 deaths from prostate cancer
were expected in 2004 (American Cancer Society, 2004). These
deaths are primarily due to metastases that are resistant to
conventional therapies. The most common site for metastasis
of prostate cancer is the bone, with patients often experiencing
intense pain, pathological fracture, hypercalcemia, and immo-
bility (see [Mundy, 2002] for review). Currently, there are few
successful treatment options for patients with bone metasta-
ses that can improve overall patient survival (Chay et al., 2002).
To address this and to identify new therapeutic targets, the
molecular mechanisms underlying prostate tumor induced
changes in the bone microenvironment need to be elucidated.
However, one of the major drawbacks in identifying these
mechanisms is the lack of animal models that mimic the mani-
festation of human prostate carcinoma skeletal metastasis.
Human bone metastases of prostate cancer are mixed
lesions, typically containing regions of invading tumor coupled
with areas of osteoblastic and osteolytic change (Keller and
Brown, 2004). Unfortunately, current metastatic prostate can-
cer animal models and cell lines lack these histological featuresCANCER CELL : MAY 2005 · VOL. 7 · COPYRIGHT © 2005 ELSEVIER INC.of clinical prostate cancers metastases or produce low rates
of metastasis to bone (Shevrin et al., 1989; Nemeth et al., 1999;
Zhau et al., 2000; Corey et al., 2002). Therefore, it is difficult to
address the full complement of molecular interactions at work
in the metastatic prostate cancer bone microenvironment using
these models.
Our current understanding of how metastatic prostate can-
cer cells induce osteoblastic lesions is poor, although several
studies have shown transforming growth factor β (TGF-β) to
play an important role in the stimulation of osteoblast prolifera-
tion and bone matrix formation (Keller and Brown, 2004). On
the contrary, more is known about osteolytic lesions induced
by the tumor cells. The interaction between the tumor and
bone stroma has been commonly referred to as the “vicious
cycle,” whereby tumor cells in the bone can secrete factors
such as parathyroid hormone related peptide (PTHrP) that
stimulate osteoblast expression of the TNF family member re-
ceptor activator of nuclear κB ligand (RANKL). By binding to
the receptor RANK, RANKL has been shown to be essential in
mediating osteoclast activation. The osteoclasts degrade the
bone matrix using a powerful array of proteinases such as the
cathepsins and matrix metalloproteinases (MMPs) (see [De-DOI 10.1016/j.ccr.2005.04.013 485
A R T I C L Elaisse et al., 2003] for review). Degradation of the bone matrix
leads to the release of TGF-β and other growth factors that in
turn stimulate tumor growth and lead to increased levels of
tumor derived PTHrP (see [Mundy, 2002] for review).
These factors outlined above contribute to our understand-
ing of how prostate tumor cells can potentially induce changes
in the bone. However, it is likely that there are many more un-
identified factors present in the tumor-bone microenvironment
that dictate how the bone stroma will respond to the metastatic
tumor cells, and vice versa. The aim of the current study was
to generate an animal model that accurately reflects the beha-
vior of human prostate cancer in the bone with respect to the
induced changes in bone matrix homeostasis, and to identify
the molecules that underlie the behavior of this disease.
Results
Establishment of a rat model of human prostate
cancer in the bone
To mimic the metastatic human prostate bone environment,
pieces of moderately differentiated prostate adenocarcinoma,
generated in rats as previously described (Kato et al., 1998),
were transplanted into the cranial region of syngeneic animals.
At early time points, little or no change in the bone density of
the calvaria was observed by X-ray radiography (Figure 1A).Figure 1. Model of prostate cancer-induced os-
teolytic and osteoblastic change
A: Postoperative X-ray analysis of the tumor (t).
Note intact calvaria.
B: At week 4, areas of osteolysis could be dis-
cerned by X-ray (arrows), and the tumor volume
also increased (dashed line represents tumor
border).
C–D: Coronal sections of the cranial bone
stained with H&E at weeks 2 and 4, respectively
(black dashed line represents intact calvaria;
arrows indicate areas of osteolysis; b denotes
bone; scale bars represent 2 mm).
E: Higher magnification of the H&E-stained sam-
ples demonstrated the presence of multinucle-
ated osteoclasts lining the TB interface at week
2. Arrows indicate osteoclasts; scale bar is
0.1 mm.
F: H&E-stained sections at week 4. Note that
more osteoclasts were observed. Scale bar rep-
resents 0.5 mm.
G: H&E stained sections of areas of osteoblastic
change at week 2. Arrows indicate osteoblasts;
nb represents new bone formation; scale bar
represents 0.02 mm.
H: H&E-stained sections at week 4 with pro-
nounced areas of osteoblastic change (arrows
indicate osteoblasts). Scale bar represents
0.5 mm.
I: H&E-stained section of the TB interface at
week 4. Osteoclasts are indicated by arrows.
J: Mean ± SD of the number of osteoclasts at
weeks 2, 3, and 4 (n = 3 for each time point).
K: Bone destruction index is calculated as per-
cent of bone underneath the tumor demon-
strating osteolysis (n = 3 for each time point).
Values are mean ± SD.
L: H&E-stained section at week 4. Arrows indicate osteoblasts (nb, new bone; cb, calvarial bone).
M: Mean ± SD of the number of osteoblasts at weeks 2, 3, and 4 (n = 3 for each time point).
N: Mean ± SD of the area of new bone per coronal section (n = 3 for each time point). Amount of new bone area formed by the osteoblasts was
also quantified.
Error bars represent standard deviation.486However, clear osteolytic lesions were visually identified in the
calvaria at week 4 (Figure 1B). Histopathological analysis of the
tumor-bone interface (TB interface) revealed both osteolytic
and osteoblastic changes over the course of the experiment
(Figures 1C and 1D). Inspection of the TB interface demon-
strated small bone defects and the presence of osteoclasts at
week 2 (Figure 1E). At week 4, osteoclasts were observed at
the TB interface, and a larger area of bone absorption in com-
parison to week 2 was noted (Figure 1F). Small areas of nodu-
lar osteoid produced by the osteoblasts were also identified at
week 2, and these areas increased through week 4 (Figures 1G
and 1H).
Under high magnification, it was clear that the osteoclast
cells were responsible for the tumor-induced osteolysis at the
TB interface, as they separated the prostate tumor cells from
the bone matrix (Figure 1I). We determined the number of os-
teoclasts present at each experimental time point in order to
examine the effects of the prostate tumor on osteoclast recruit-
ment and activity. Several coronal sections from each rat were
examined, and approximately fifty osteoclasts per section were
found to accumulate at the TB interface by week 2 (Figure 1J).
These levels remained elevated at the 3- and 4-week time
points. In comparison, no osteoclasts were recruited to the site
of sham operations in the control animals at days 0 or 14 (dataCANCER CELL : MAY 2005
A R T I C L Enot shown). We also examined the extent of bone destruction
in several sections from each rat using a “bone destruction
index,” which refers to the length of osteolysis per length of
cranial bone beneath the transplanted tumors. We found that
the bone destruction index was on average 30% at week 2,
and that the extent of destruction increased up to 90% at week
4 (Figure 1K). The number of osteoclasts at each time point did
not correlate with the extent of bone destruction, suggesting
that the prostate tumor cells recruit the osteoclasts rapidly to
the TB interface, and induce osteolytic lesions gradually.
Our rat model also displayed large areas of osteoblast activ-
ity and nodular-osteoid formation. These osteoid formations,
because of their amorphous structure, were easily identified in
comparison to the laminar bone of the calvaria (Figure 1L). We
counted the osteoblasts present at the TB interface in several
coronal sections from each rat and found that the numbers
increased from approximately 500 at week 2 to 1000 at weeks
3 and 4 (Figure 1M). We measured the tumor-induced osteoid
formations and found that they increased at all time points,
which correlated to the number of osteoblasts (Figure 1N).
We also generated a spinal implant model, representing car-
tilagenous rather than membraneous bone, and our findings
were similar to those described for the cranial model (data not
shown). No osteoblastic or osteolytic changes were observed
when sham surgeries were performed on control rats in either
the cranial or spinal models (data not shown).
Importantly, the histological observations at the TB interface
in our animal model mimic the histological features of meta-
static bone lesions in human prostate cancers. The model
therefore presents an exciting opportunity to examine the mo-
lecular mechanisms underlying how tumor cells can induce os-
teoblastic and osteolytic changes in the bone lesions.
Expression of PTHrP, RANKL, and OPG
at the TB interface
We next characterized the expression of molecules known to
be important for pathological changes in the bone environ-
ment, including PTHrP, RANKL, and osteoprotegerin (OPG)
(Mundy, 2002). Using quantitative real-time PCR, we compared
the mRNA expression of these molecules at the TB interface
to the tumor area alone (Figure 2A). The TB interface was com-
prised of tumor cells invading into the bone, osteoblasts induc-
ing osteoid formation, and osteoclasts mediating osteolysis,
while the tumor area was primarily comprised of prostate tumor
cells with occasional stromal elements (Figures 2B and 2C).
PTHrP in the bone environment is an important regulator of
osteoblast function. PTHrP was constantly expressed in the
tumor area alone over the course of the experiment, although
the levels tended toward a decrease with time (Figure 2D). In
comparison, the levels of PTHrP were much higher at the TB
interface over the course of the experiment. These observa-
tions are consistent with the “vicious cycle” concept whereby
bone-derived factors stimulate tumor PTHrP expression.
PTHrP stimulates the expression of RANKL by osteoblasts and
is essential in mediating osteoclast activation (Mundy, 2002).
In our model, RANKL was expressed at a significantly higher
level at the TB interface compared to the tumor alone at each
experimental time point (Figure 2E). The effects of RANKL can
be inhibited by the binding of a soluble decoy receptor mole-
cule, OPG (Simonet et al., 1997). Real-time PCR analysis of
OPG expression demonstrated that there was a significantlyCANCER CELL : MAY 2005higher level of OPG expression at the TB interface at week 2
in comparison to the tumor area alone (Figure 3F). However, at
the 3- and 4-week time points, a significant decrease in OPG
expression was observed at the TB interface. This decrease in
OPG over time, in contrast to the persistently high levels of
RANKL and PTHrP, is consistent with the observed increases
in osteoclast activation and bone destruction occurring at the
TB interface.
Several reports have recently suggested that RANKL is also
expressed by the prostate tumor cells (Brown et al., 2001). Al-
though we observed RANKL mRNA expression in the tumor
area alone (Figure 2E), immunohistochemical staining for
RANKL demonstrated that the osteoblasts were the main
source of RANKL in our model (Figure 2G), as little or no stain-
ing was observed in the osteoclasts or in the tumor cells (Fig-
ures 2H and 2I).
Gene expression at the TB interface
Having demonstrated that the rat model was recapitulating the
histological features of metastatic human prostate cancer in
the bone, we used microarray analysis to examine the expres-
sion of 1200 genes at the TB interface and tumor areas from
both the cranial and spinal models at the 4-week experimental
time point. Several genes showed significant elevation at the
TB interface in both models, including apolipoprotein-D
(Apo-D), matrix metalloproteinase-7 (MMP-7), and cathepsin-K
(Cat-K) (Figure 3A). Genes that were significantly decreased in-
cluded adenine nucleotide translocator 2 (ANT2), ATPase, Ca2+
transporting, cardiac muscle (BCAT), aquaporin-8 (AQP-8), and
channel-inducing factor (CHIF). The presence of genes that are
differentially expressed in both the cranial and spinal models
suggested common mechanisms of osteolysis that are inde-
pendent of intramembraneous or intracartilaginous ossifi-
cation.
Real-time PCR was used to validate the expression of candi-
date genes identified by microarray analysis. We also assessed
the sequential expression of these genes at the TB interface
and tumor areas in order to determine if there was a correlation
with osteolytic and/or osteoblastic changes. Apo-D is a mem-
ber of the lipocalcin family of hydrophobic protein transporters.
We found that the expression of Apo-D gradually increased
over time and was significantly higher at the TB interface in
comparison to the tumor area at all time points (Figure 3B).
The exact role of Apo-D in prostate tumor progression remains
unclear; however, it may be involved in the growth and devel-
opment of hormone-responsive tissue because of an ability to
bind hormones such as progesterone (Rassart et al., 2000).
Significantly higher mRNA levels of MMP-7 were found at
the TB interface in comparison to the tumor area alone. Inter-
estingly, MMP-7 expression showed a good correlation with
the bone destruction index (Figure 1K). MMP-7 is one of the
smallest members of the MMP family and is capable of hy-
drolyzing a vast array of extracellular matrix (ECM) and non-
ECM derived substrates (see [Lynch and Matrisian, 2002] for
review). However, no role for MMP-7 in the pathological bone
environment has been described.
Cat-K, a powerful cysteine proteinase produced by osteo-
clasts, has an important role in bone matrix turnover (Gowen et
al., 1999), and the mRNA expression levels at the TB interface
correlated with the number of osteoclasts (Figures 1J and 3D).
Little Cat-K expression was observed in the tumor area. The487
A R T I C L EFigure 2. Characterization of the rat prostate bone invasion model
A: For mRNA analysis, the samples were divided into areas of TB interface (rectangle) and tumor area alone (oval).
B: H&E-stained section of the TB interface comprised of areas of tumor (t), bone (b), and new bone (nb).
C: H&E-stained section of the tumor area comprised primarily of tumor cells (t).
D–F: Real-time PCR analysis of PTHrP, RANKL, and OPG gene expression over time was performed on three rats from each experimental time point. Striped
bars represent values obtained from the tumor bone interface, while solid bars represent the values obtained from the tumor area alone. To obtain the
ratios, target gene expression was normalized to GAPDH. *, p < 0.05; **, p < 0.01; ***, p < 0.001.
G–I: Immunohistochemical staining for RANKL in the osteoblasts (G) osteoclasts (H) and tumor cells (I) at week 4. Multiple sections from each time point
were examined with similar results.
Error bars represent standard deviation.identification of Cat-K at the TB interface demonstrated that
the microarray data obtained was consistent with previously
published reports on the role of this proteinase in osteolysis.
Several genes were also significantly decreased at the TB
interface in comparison to the tumor area alone. Upon analysis
with real-time PCR, no significant differences between the TB
interface and the tumor were observed at any experimental
time point for ANT-2, BCAT, and CHIF (data not shown). The
expression of AQP-8, a member of the transmembrane water
channel aquaporins (Koyama et al., 1997), also showed no dif-
ference at weeks 2 to 3, but a significant reduction in the ex-
pression of AQP-8 at the TB interface compared to the tumor
alone was noted at week 4 (Figure 3E).
MMP-7 is expressed by osteoclasts in vivo and in vitro
A number of studies have shown that the MMPs are important
in bone matrix development and homeostasis and that broad-
spectrum MMP inhibitors (MMPIs) are efficient in the preven-488tion of osteolysis (see [Delaisse et al., 2003] for review). The
identification and validation of MMP-7 mRNA at the TB in-
terface coupled to the promise of MMPIs in the treatment of
osteolysis led us investigate the role of MMP-7 at the TB inter-
face. Immunohistochemical analysis revealed that cells resem-
bling osteoclasts, present at the TB interface at week 4, were
positive for MMP-7 (Figures 4A and 4B). To confirm that the
cells expressing MMP-7 were osteoclasts, we used the histo-
chemical marker for activated osteoclasts, tartrate-resistant
acid phosphatase (TRAP), in adjacent serial tumor sections
(Figures 4C and 4D). We also observed that MMP-7 was not
expressed by the prostate tumor cells or in areas where osteo-
blastic changes were occurring, thereby suggesting that the
role of MMP-7 was connected to prostate cancer-induced os-
teolysis (Figures 4E and 4F). To corroborate evidence that os-
teoclasts can express MMP-7, we examined an immortalized
osteoclast cell line (Hentunen et al., 1999). RT-PCR and immu-
noblot analysis confirmed the expression of MMP-7 in theseCANCER CELL : MAY 2005
A R T I C L EFigure 3. Identification of differentially expressed
genes at the TB interface
A: Comparative microarray analysis of genes
expressed at the TB interface and the tumor
area. The upregulated values represent the fold
increase in expression of a particular gene at
the TB interface when compared to the tumor
alone, and the downregulated values represent
the inverse reciprocal fold decrease in expres-
sion of candidate genes at the TB interface
when compared to the tumor alone.
B–E: Apo-D, MMP-7, Cat-K, and AQP-8: GAPDH
mRNA ratio at the tumor bone interface (striped
bars) and tumor area alone (solid bars). *, p <
0.05; **, p < 0.01 (n = 3 for each experimental
time point).
Error bars represent standard deviation.cells (Figures 4G and 4H). Collectively, these data demonstrate
that MMP-7 is expressed both in vivo and in vitro by osteo-
clasts.
MMP-7 cleaves RANKL to a soluble active form
We hypothesized that osteoclast MMP-7 expression was
linked to osteolysis based on the positive correlation between
MMP-7 expression and bone destruction (Figures 1K and 3C).
Given that MMP-7 has a broad extracellular matrix (ECM) sub-
strate specificity, an obvious role for MMP-7 expression by the
osteoclasts would be in the degradation of bone matrix. How-
ever, MMP-7 has often been associated with “sheddase” activ-
ity rather than bulk degeneration of the ECM. In this regard,
MMP-7 has been shown to convert membrane-bound forms of
TNF family members such as TNF and FasL to soluble active
forms (see [Lynch and Matrisian, 2002] for review). Interest-
ingly, the levels of the TNF family member RANKL also corre-
lated with the extent of bone destruction in our model (Figures
1K and 2E). In addition, RANKL contains putative metallopro-
teinase cleavage sites (Nakashima et al., 2000), and transgenicCANCER CELL : MAY 2005animals expressing a soluble version of RANKL exhibit exten-
sive osteoporosis (Mizuno et al., 2002). We therefore hypothe-
sized that the potential mechanism through which MMP-7 may
be promoting osteolysis was via the solubilization of RANKL,
which is an essential mediator of osteoclast activation.
To determine if MMP-7 was capable of cleaving RANKL, full-
length RANKL protein was generated using an in vitro transla-
tion system. Analysis of translation products generated from
the RANKL expression vector demonstrated the predicted full-
length unglycosylated 38 kDa product (Figure 5A, control lane).
After 6 hr incubation, enzymatically active MMP-7 clearly pro-
cessed RANKL into two major fragments with molecular
weights of approximately 24 kDa and 12 kDa (Figure 5A). Since
RANKL is sensitive to metalloproteinase-mediated cleavage, we
tested other bone-relevant MMPs. Interestingly, MMP-3, which
shares similar ECM and non-ECM substrates with MMP-7, was
also found to cleave RANKL, while other MMPs, such as
MMP-2, MMP-9, and MMP-13, did not (Figure 5A). In the pres-
ence of the broad-spectrum MMP inhibitor BB-94, neither
MMP-3 nor MMP-7 processed RANKL, confirming that489
A R T I C L EFigure 4. Localization of MMP-7 expression at the TB interface
A–B: Immunohistochemistry for MMP-7 at week 4. Osteoclasts are indi-
cated by arrows. Scale bar = 0.05 mm (A) and 0.02 mm (B).
C–D: TRAP staining (red) as a marker for osteoclasts (arrows). Scale bar =
0.05 mm (C) and 0.02 mm (D).
E–F: MMP-7 immunohistochemistry was negative in the tumor area and
areas of osteoblastic change, respectively. Scale bars = 0.05 mm.
G–H: MMP-7 was also detected in OCLBCL-XL/TAG (OCL) cells at the mRNA
and protein levels, respectively. MM refers to the molecular weight marker
in base pairs (G) and in kDa (H). Suffixes CM and LYS refer to conditioned
media and lysate, respectively. Cell lines known to be positive and nega-
tive for MMP-7 were used as positive controls.MMP-3 and MMP-7 enzymatic activity was responsible for the
observed proteolysis (Figure 5B). The enzymatic activity of
each MMP was confirmed by incubation with fluorescently
quenched gelatin. Within 150 min, all of the MMPs tested for
RANKL cleavage ability showed evidence of gelatin degrada-
tion as measured by an increase in fluorescence (Figure 5C).
To determine the site of RANKL cleavage, N-terminal amino
acid sequencing was performed on the major fragment gener-
ated by MMP-7 upon incubation with recombinant RANKL
(Figure 5D). The sequence of this product was MEGSPLDVAQ,
which corresponds to residues 146–155 in the stalk region of
RANKL. The cleavage of RANKL in the stalk region suggests
that MMP-7 processing results in the release of an active li-
gand from the cell surface (Figure 5E).
Next, we addressed if MMP-7 could access and cleave gly-
cosylated RANKL on the cell surface. The RANKL protein ex-
pression vector was transfected into the Cos-7 cell line, which490does not endogenously express RANKL (data not shown). Cell
lysates showed the presence of a predicted 45 kDa glycosy-
lated membrane-associated RANKL protein (Figure 5F, control
lane, top panel). Addition of MMP-7 to the transfected cells
resulted in full-length RANKL being cleaved from the cell sur-
face and the detection of an expected 24 kDa soluble form of
RANKL in the conditioned media (Figure 5F; middle panel).
Similar results were also obtained for MMP-3, although the
amount of soluble RANKL produced was significantly less. The
addition of BB-94 completely inhibited the MMP-dependent
solubilization of RANKL from the cell surface (Figure 6F). These
data indicate that MMP-7 is capable of generating soluble
RANKL from the surface of RANKL-expressing cells.
MMP-7-solubilized RANKL promotes
osteoclast activation
Next we asked if the soluble form of RANKL generated by
MMP-7 was functional. Monocyte precursors from human pe-
ripheral blood were isolated and treated with normal media
(control) or media containing either MMP-7-solubilized or full-
length RANKL. Histochemical analysis of TRAP and actin ring
formation demonstrated relatively few mature osteoclasts in
the controls compared to cells treated with MMP-7-solubilized
RANKL and full-length RANKL (Figures 6A and 6C versus Fig-
ures 6B and 6D and data not shown). The numbers of mature
osteoclasts in full-length RANKL- and MMP-7-cleaved RANKL-
treated cells were similar, suggesting that MMP-7-solubilized
RANKL was active and efficient at osteoclast activation (Figure
6E). In addition, osteoclasts activated by either full-length or
MMP-7-solubilized RANKL were functional and capable of
forming resorptive pits in dentin slices (Figure 6F versus Figure
6G and data not shown). MMP-7-solubilized RANKL was com-
parable to full-length RANKL with respect to the number of
resorptive pits formed on the dentin surface (Figure 6H).
Tumor-induced osteolysis is significantly reduced
in MMP-7-deficient mice
To specifically address the contribution of MMP-7 to tumor-
induced osteolysis, the rat prostate tumor tissue was trans-
planted to the calvarias of 6-week-old immunocompromised
MMP-7 wild-type and MMP-7-deficient mice. Micro-CT scan-
ning revealed that, by week 3, there was extensive osteolysis
in the calvaria of the wild-type mice, while noticeably less os-
teolysis was observed in the MMP-7-deficient animals (Figures
7A and 7B). Segmentation analysis of the CT data to quantitate
the density of the wild-type and MMP-7-deficient mouse skulls
revealed that there was significantly less bone in the wild-type
calvaria, consistent with extensive osteolysis (Figure 7C). No
difference was observed in the density of the calvaria from age-
matched nontransplanted wild-type and MMP-7-deficient
mouse skulls, suggesting that the MMP-7-deficient animals
had normal bone density (data not shown). Histological analy-
sis of the TB interface confirmed extensive osteolysis at the
TB interface in wild-type mice compared to MMP-7-deficient
animals (Figures 7D and 7E). Analysis of the bone destruction
index indicated a 66% reduction in bone destruction in MMP-
7-deficient mice compared to wild-type controls (Figure 7F).
As expected, only the osteoclasts in the wild-type mice
stained positive for MMP-7 (Figures 7G and 7H). Furthermore,
significantly fewer osteoclasts were observed at the TB inter-
face in the MMP-7-deficient mice (Figure 7H). To confirm thatCANCER CELL : MAY 2005
A R T I C L EFigure 5. RANKL is cleaved by MMP-7
A: Recombinant MMP-2, -3, -7, -9, and -13 were incubated with in vitro-translated RANKL. Arrow indicates full-length RANKL. Closed arrows indicate 24 kDa
and 12 kDa RANKL cleavage products.
B: RANKL was incubated with MMP-3 and MMP-7 in the presence of the broad-spectrum MMP inhibitor BB-94.
C: The activity of each of the MMPs was tested against a fluorescently quenched common substrate, gelatin.
D: Recombinant RANKL was also cleaved with recombinant MMP-7 and the cleavage products were analyzed by N-terminal amino acid sequencing.
E: MMP-7 cleavage of RANKL occurred in the stalk region at 145Met-Met146. Numbers 1–316 represent the amino acids in full-length RANKL (1–48, cytoplas-
mic region; 49–69, transmembrane region; 70–157, stalk region; and 158–316, active ligand moiety).
F: Immunoblot analysis of RANKL cleavage from the cell surface of RANKL-transfected Cos-7 cell lines in the presence or absence of the broad-spectrum
MMP inhibitor BB-94 (5 µM) (top and middle panel). Actin was used to control for equal loading of the lysate samples (lower panel). MM refers to the
protein molecular weight in kDa.MMP-7 was mediating RANKL solubilization in vivo, we immu-
noprecipitated the soluble form of RANKL from the TB inter-
face lysates from wild-type and MMP-7-deficient mice. Soluble
RANKL was clearly detected in the TB interface lysates from
the wild-type mice, while little or no soluble RANKL was de-
tected in the MMP-7-deficient animals (Figure 7I). Soluble
RANKL was not detected in the lysates of the tumor area alone
from either group. These data indicate that stromal MMP-7
clearly contributes to the solubilization of RANKL at the TB
interface.
Discussion
Using a model of rat prostate cancer in the bone that features
both osteolytic and osteoblastic changes, we identified MMP-7
as a candidate gene involved in prostate cancer-induced bone
resorption. Further investigation demonstrated that MMP-7
was secreted by osteoclasts at the TB interface, and pro-
cessed RANKL to a soluble form capable of promoting osteo-
clast activation and bone resorption (Figure 8). The use of
MMP-7-deficient mice demonstrated that MMP-7 in the tumor-
bone microenvironment is an important mediator of prostate
cancer-induced osteolysis.CANCER CELL : MAY 2005An animal model of prostate cancer
in the bone environment
To date, human prostate cancer metastasis in the bone has
been difficult to mimic in animal models. In existing models of
prostate carcinogenesis such as the transgenic adenocarci-
noma of mouse prostate model (TRAMP) and the SV-40 proba-
sin transgenic rat model, lymph node and pulmonary metasta-
ses are common, but the induction of bone metastases from
the primary tumor site is rare (Gingrich and Greenberg, 1996;
Asamoto et al., 2001). Using available prostate cancer cell
lines, it has also been difficult to mimic the clinical patterns of
osseous metastasis of human prostate cancer. These models
include tail vein, intracardiac, or orthotopic injection of prostate
cancer cell lines or the use of femoral human bone implanted
into nude mice (Arguello et al., 1988; Zhang et al., 2001; Fisher
et al., 2002; Nemeth et al., 1999). Our bone invasion model
of rat prostate cancer requires a simple surgical technique of
transplantation of rat prostate tumor tissue onto the surface of
the calvaria or spinal column, ensuring that both intramembra-
neous and cartilaginous bone can be easily examined. The re-
sulting tumors are moderately differentiated rat prostate ade-
nocarcinoma with osteolytic and osteoblastic changes that are
similar to the histopathological features of bone metastasis of
human prostate cancer (Keller and Brown, 2004). Our model491
A R T I C L EFigure 6. MMP-7-solubilized RANKL promotes os-
teoclast activation and bone resorption
A–B: Control cells stained positive for TRAP activ-
ity (dark brown granules) but were typically
mononuclear (arrows), while MMP-7-solubilized
RANKL-treated osteoclasts were active, as indi-
cated by positive TRAP staining and multinucle-
ation (arrows).
C–D: Actin (green) cortical rings were rarely de-
tected in untreated control cells, while MMP-7-
soluble RANKL-treated osteoclasts displayed
actin cortical rings structures and multinucle-
ation (arrows).
E: The osteoclasts determined by cytochemistry
were counted and expressed as a percentage
of the total number of cells. Gray and dotted
bars indicate the percentage of osteoclasts as
determined by TRAP and actin staining, respec-
tively. Bars = mean ± SD.
F–G: Control and MMP-7-solubilized RANKL-
treated osteoclasts were incubated on dentin
slices, and the number of resorptive pits quanti-
tated.
H: The total number of pits on each disc was
counted, and the mean standard deviation of
the number of pits formed is displayed. *, p <
0.05 (n = 5 for each assay).has limitations in that it does not represent the process of hu-
man prostate-to-bone metastasis or the typical location in the
bone where metastatic prostate tumors arise. However, as the
model accurately reflects how human prostate cancers behave
in the bone, we feel that these limitations are outweighed by
the potential for defining how tumor cells can effect changes
in bone matrix homeostasis. In this regard, our animal model
has proved extremely useful in allowing us to identify key
factors driving tumor-induced osteoblastic and osteolytic
changes.
MMP-7 in the pathological bone environment
Over the past decade, it has become increasingly clear that
the MMPs are exquisite regulators of cell:cell communication,
and this is primarily achieved through the solubilization of non-
matrix molecules such as cytokines and growth factors. For
example, MMP-7 has been shown to process TNF, FasL, and
E cadherin, and as a consequence of these actions, profound
changes on cellular behavior have been observed (see [Lynch
and Matrisian, 2002] for review). Therefore, the detection of
MMP-7 and its increased expression over time at the TB inter-
face made it an interesting target to pursue in order to better
understand the biology of the prostate tumor-induced osteo-
lysis.
The solubilization of RANKL by MMP-7 appears to be at
least one mechanism by which MMP-7 mediates osteolysis in
our model. The current theory is that osteoclasts become acti-
vated via the direct interaction of the immature osteoclast cell
with the RANKL-expressing osteoblast (see [Mundy, 2002] for
review). Therefore, one major implication for the presence of
MMP-7-solubilized RANKL at the TB interface is that it allows
the immature osteoclast to circumvent the requirement for di-
rect interaction with osteoblasts. To support this argument, sol-
uble RANKL has been detected in vivo in pathological bone-492degrading diseases such as multiple myeloma (Terpos et al.,
2004). Furthermore, in transgenic animals, the targeted expres-
sion of soluble RANKL in hepatocytes has been shown to
cause severe osteolysis in mice (Mizuno et al., 2002).
Although RANKL expression was mainly localized to the os-
teoblasts in our study, previous reports have demonstrated
RANKL expression in primary and bone metastatic prostate
cancers (Brown et al., 2001). The expression of membrane-
bound RANKL was also demonstrated by Keller and col-
leagues in the LnCAP prostate cancer cell line and the LnCAP-
derived bone homing metastatic cell line, C4-2B (Zhang et al.,
2001). Interestingly, this group also showed that these cell lines
secrete a 24 kDa soluble version of RANKL which is the same
size as the soluble RANKL generated by MMP-7. Furthermore,
Bowden and colleagues have observed MMP-7 expression in
the LnCAP prostate cancer cell line, suggesting that, at least
in vitro, MMP-7 may be responsible for the secreted 24 kDa
version of RANKL observed in both LnCAP and C4-2B (Klein
et al., 1997). In our in vivo model, little or no MMP-7 expression
was detected in the prostate tumor cells, and we clearly dem-
onstrated the importance of stromal MMP-7 to prostate tumor-
induced osteolysis by using MMP-7-deficient animals. There-
fore, it appears that in the pathological bone environment,
MMP-7 can be derived from both the stroma and, potentially,
the prostate tumor cells, and by solubilizing RANKL, MMP-7
promotes osteoclast activation and bone resorption (Figure 8).
MMPs and RANKL solubilization
In the current study, soluble RANKL was detected in the TB
interface lysates from the MMP-7-deficient animals, albeit to a
much lesser extent than the wild-type controls, suggesting that
other proteinases in addition to MMP-7 contribute to RANKL
cleavage during tumor-induced bone destruction. MMP-3 has
been shown to be expressed by osteoblasts (Breckon et al.,CANCER CELL : MAY 2005
A R T I C L EFigure 7.MMP-7-deficient animals exhibit less os-
teolysis and decreased shedding of RANKL
A–B: The calvaria of immunocompromised age-
matched male MMP-7-deficient mice and wild-
type mice were transplanted with rat prostate
cancer tissue. After 3 weeks, large areas of os-
teolysis (arrows) were observed in the wild-type
animals (A) compared to the MMP-7-deficient
animals (B).
C: Quantitative segmentation analysis of the
µCT scan data using Amira software demon-
strated that there was significantly less bone in
the MMP-7 wild-type animals (mean ± SD, 4
wild-type and 6 MMP-7 null mice; *, p < 0.05).
D–E: Histological analysis of H&E-stained sections
from the tumors growing in the wild-type (D)
and MMP-7-deficient animals (E) demonstrated
that there was much less invasion of prostate
tumor cells in the MMP-7-deficient animals (the
dashed line represents area of resorbed cal-
varia, while the solid line represents the intact
calvaria). Arrows in D represent the invading tu-
mor cells. Scale bar is 1 mm.
F: Bone destruction index. Mean ± SD, n = 4 wild-
type and n = 6 MMP-7 null. *, p < 0.05.
G–H: Using immunohistochemistry, MMP-7 was
only detected in the wild-type osteoclasts (G)
and not in the MMP-7-deficient osteoclasts (H).
I: Osteoclasts at the TB interface were counted.
Mean ± SD, n = 4 wild-type and n = 6 MMP-7
null. **, p < 0.01.
J: Immunoprecipitation using antibodies di-
rected toward the N terminus of RANKL demon-
strated that soluble RANKL (sRANKL) was present
in the TB interface lysates from the MMP-7 wild-
type mice. The numbers above each lane re-
present the individual mouse numbers from
mice in the wild-type and MMP-7-deficient
groups. As positive controls, direct immunoblot
analysis of full-length RANKL (full RANKL) from
transfected Cos-7 lysates, which migrates at ap-
proximately 45 kDa, and recombinant RANKL
(rec RANKL), which migrates at approximately
35 kDa, were added. MM refers to the molecu-
lar marker in kDa.
Error bars represent standard deviation.1999) and is capable of cleaving RANKL (Figure 5). Therefore,
the expression of MMP-3 at the TB interface may also be con-
tributing to the cleavage of RANKL in our model. Previous
in vitro reports have also demonstrated that MMP-1, MMP-14,
and members of the ADAM (a disintegrin and metalloprotei-
nase) family, ADAM-17 and ADAM-19, are capable of cleaving
RANKL to a soluble form (Chesneau et al., 2003; Schlondorff
et al., 2001). Although these metalloproteinases may be in-
volved in the processing of RANKL, no in vivo evidence for a
role in bone resorption currently exists. We also examined
other MMPs known to have roles in the bone environment, in-
cluding MMP-9 and MMP-13, as mice deficient in these en-
zymes have been reported as having defects in osteoclast
function and bone development (Vu et al., 1998; Inada et al.,
2004). However, neither MMP-9 nor MMP-13 was capable of
processing RANKL to a soluble form, suggesting that they af-
fect osteoclast activity either by the processing of extracellular
matrix or through the solubilization of other nonmatrix factors.CANCER CELL : MAY 2005The clinical relevance of MMP-7 in the metastatic
prostate bone tumor
The identification of MMP-7 expression by osteoclasts and the
elucidation of how this proteinase contributes to prostate tu-
mor-induced osteolysis makes it an exciting therapeutic target
for the treatment of this disease. A number of recent studies
have shown that there is great potential for the use of MMPIs
in the treatment of prostate and breast osteolytic lesions (Lee
et al., 2001; Nemeth et al., 2002; Winding et al., 2002). These
in vivo studies demonstrated that the administration of broad-
spectrum MMPIs to animals with metastatic bone tumors not
only reduced the extent of tumor-induced osteolysis, but also
inhibited the growth of the tumor. However, cautionary tales
exist for the use of broad-spectrum MMPIs in the clinical set-
ting. Although for the most part, the aberrant expression of
MMPs appears to contribute to tumor progression, in some
instances, the increased expression of MMPs can suppress tu-
morigenesis and inhibit angiogenesis (see [Coussens et al.,493
A R T I C L EFigure 8. Role of MMP-7 in the pathological bone environment
In our model, MMP-7 is expressed by the osteoclasts (1). Previous studies
have shown that MMP-7 can be expressed by prostate cancers (2). The
secretion of MMP-7 results in the solubilization of RANKL being presented
by the osteoblast or tumor cells in the bone microenvironment (3). Soluble
RANKL is then capable of mediating the activation of osteoclasts at or
near the TB interface, resulting in bone degradation (4). Blue numbers in
the diagram illustrate how MMP-7-solubilized RANKL works in our model,
while gray numbers represent how MMP-7 derived from the tumor cells can
drive RANKL solubilization and osteoclast activation.2002] for review). In this regard, the identification of the role of
specific MMPs in tumor progression is important with respect
to minimizing the potential side effects from unexpected pro-
tective functions of the MMPs.
In conclusion, we have established a model of rat prostate
cancer in the bone environment that features areas of osteo-
lytic and osteoblastic change. We used the model to identify
genes that are expressed in the tumor-bone interface com-
pared to the tumor alone. This approach identified the aberrant
regulation of several genes, including cathepsin-K, an osteo-
clast-produced enzyme known to contribute to bone resorp-
tion, and revealed MMP-7 as another proteolytic enzyme
whose expression correlated with tumor-induced osteolysis.
We made the observation that MMP-7 was also produced by
osteoclasts, and was a major contributor to prostate cancer-
induced osteolysis. In addition, MMP-7 cleaved RANKL to a
soluble active form in vitro and in vivo, establishing a mecha-
nism for MMP-7 action in bone destruction. These results
make MMP-7 an attractive therapeutic target for the control of
cancer-induced bone osteolysis.
Experimental procedures
Animal models and tissue preparation
The rat prostatic carcinoma tissues used in this experiment were estab-
lished from primary tumors that developed in the dorsolateral prostate of
F344 rats receiving combined treatments of DMAB (3-2# dimethyl 4-amino-
biphenyl) and testosterone propionate as previously described (Kato et al.,
1998). Tumors were subsequently transplanted into 6-week-old F344 male
rats. Tumor growth at the implanted sites and body weight were measured
weekly, and bone matrix turnover was assessed by X-ray radiograms (Shi-
mazu, XED125M). Tumors were also implanted into 6-week-old MMP-7-
deficient (n = 6) and wild-type control immunodeficient mice (n = 4). These
mice were generated by breeding MMP-7-deficient mice (c57BL/6 back-
ground) to RAG-2 (recombination activation gene-2) immunodeficient mice494(c57BL/6 background from Taconic) in order to generate double knockout
animals. Littermates that were wild-type for MMP-7 but knockout for
RAG-2 were used as controls (Wilson et al., 1997; Shinkai et al., 1992).
Micro computer tomography (µCT) scanning (Concorde) and quantitation of
osteolytic lesions using segmentation analysis (Amira) were performed at
weeks 1, 2 and 3 posttransplantation. Animals were sacrificed at week 3
based upon µCT scan analysis. After sacrifice, the samples were divided in
two with one half used for histology. The other half was separated into
tumor area alone or tumor-bone interface. These samples were then flash
frozen for microarray analysis or protein lysis. For histological examination
and immunohistochemistry, the samples were fixed with periodate-lysine-
paraformaldehyde (PLP) at 4°C for 48 hr. The tissues were then transferred
into a decalcification solution (15% EDTA with glycerol [pH 7.4–7.5]) for 4
weeks and were subsequently paraffin-embedded.
Microarray analysis, real-time PCR, and RT-PCR
Calcified frozen specimens from the 4-week time point were serially sec-
tioned in 10 µm thick slices, and at least ten slides per rat were microdis-
sected, with careful separation of the tumor bone interface (TB interface)
and the tumor areas. Equal amounts of total RNA were extracted from each
microdissected population, pooled, and amplified using Atlas SMART probe
amplification kit (Clontech). Probe synthesis of cDNA arrays, poly(A)+ RNA
enrichment, and 32P labeling were performed according to the manufactur-
er’s instructions (SMART PCR cDNA synthesis Kit; Clontech). An Atlas Rat
1.2 Array (Clontech) was used for comparing gene expression profiles be-
tween TB interface and the tumor areas. Signals were detected and ana-
lyzed by image analyzer (FLA-3000G; Fujifilm) with Array Gauge software
(Fujifilm).
Real-time quantitative PCR was performed on cDNA isolated from each
area. 2 µl of cDNA samples was added to 20 µl reactions using FastStart
DNA Master SYBR Green I and a Light Cycler apparatus (Roche Diagnostics).
Primers used were: for Apo-D, 5#-GTG-CGA-AAC-AAG-GAG-CTG-CGC-3#
and 5#-TGG-CGA-TGT-CGA-TGT-CAT-TAG-A-3#; for MMP-7, 5#-GTG-GCA-
TTC-CAG-AAC-TGT-CAC-C-3# and 5#-CCT-AGA-GTG-TTT-CCT-GGC-
CCA-T-3#; for cathepsin K, 5#-CAG-GAA-CAC-AAA-TGC-ATC-ATG-G-3#
and 5#-GCT-GTT-TCT-GTC-CCA-AAT-TCC-A-3#; for AQP-8, 5#-GAA-CTG-
CTC-TTC-CTC-TTG-CGA-A-3# and 5#-ACC-GTG-AAT-GTG-ATC-TCC-
TTG-G-3#. Initial denaturation at 95°C for 10 min was followed by 40 cycles
with denaturation at 95°C for 15 s, annealing at 60°C for 5 s, and elongation
at 72°C for 30 s. The fluorescence intensity of the double-strand-specific
SYBR Green I, reflecting the amount of formed PCR product, was moni-
tored at the end of each elongation step. GAPDH mRNA levels were used
to normalize the sample cDNA content. For reverse transcription PCR (RT-
PCR) analysis of MMP-7 expression in vitro, the following primers were
used after a standard reverse transcription reaction for cDNA generation:
MMP-7 sense 5#-TGG-AGT-GCC-AGA-TGT-TTG-CAG-3#, and anti-sense,
3#-TTT-CCA-TAT-AGC-TTC-TGA-ATG-CCT-5#. PCR conditions for MMP-7:
1 cycle of 95°C for 5 min, and 35 cycles of 95°C for 60 s, 57°C (MMP-7) for
60 s, and 72°C for 2 min. The expected base pair (bp) product for MMP-7 was
519 bp.
Immunohistochemistry and cytochemistry
For the in vivo detection of MMP-7 and RANKL, sections were rehydrated
through a series of ethanols, and endogenous peroxidases were quenched
in 0.6% H2O2 in methanol for 15 min. For antigen retrieval, the sections
were brought to boiling in 0.1 M citrate buffer (pH 6.0). Using standard
blocking criteria, the sections were blocked for 1 hr at room temperature.
MMP-7 or RANKL (Shattuck-Brandt et al., 1999; Santa Cruz, sc-7628) anti-
body were diluted (1:100) in blocking solution, and the sections were incu-
bated overnight at 4°C. After washing, the slides were incubated with bio-
tinylated species-specific secondary antibodies diluted 1:500 for 30 min
(Vector Laboratories), washed, and then incubated with avidin-peroxidase
complex (ABC, Vector Laboratories) for 30 min. The slides were developed
using diaminobenzidine tetrahydrochloride (DAB) (Sigma) substrate. The
sections were counterstained with hematoxylin, dehydrated, and perma-
nently mounted. Species-specific IgG isotype were added in lieu of primary
antibody as controls, and these sections demonstrated no detectable
staining.
TRAP assays were performed to detect activated osteoclasts in vitro and
in vivo according to manufacturer’s instructions (Sigma). In addition, osteo-CANCER CELL : MAY 2005
A R T I C L Eclasts were also identified in vitro by fluorescent actin ring staining using
Oregon Green 488 phalloidin (1:1,000, Molecular Probes) as per manufac-
turer’s instructions.
Immunoblotting and immunoprecipitation
Conditioned media and cell or tumor and tumor-bone lysates were collected
using standard procedures. All samples were carefully measured for total
protein content using a BCA assay (Pierce) to ensure equal loading. For
immunoprecipitation (IP), 2 mg of tissue lysates was precleared with protein
sepharose-G (Pharmacia) and then incubated overnight at 4°C with 1 µg of
an antibody that recognized the N terminus of RANKL (sc-7268, Santa
Cruz). Soluble RANKL was then precipitated by the addition of protein
sepharose G for 1 hr at 4°C. Loading buffer was added and the samples
were boiled prior to being resolved on 15% SDS-PAGE gels and then trans-
ferred onto nitrocellulose. The blots were blocked using standard blocking
reagents and then incubated in primary antibody for the N terminus of
RANKL (diluted 1: 1,000 in blocking solution; Alexis Biochemicals) or
MMP-7 (1: 10 in blocking solution [Shattuck-Brandt et al., 1999]) overnight
at 4°C with shaking. The blots were washed and incubated for 1 hr with a
biotinylated anti-species secondary antibody (1:10,000; Vector Laborato-
ries). After washing, the blots were incubated for 30 min with streptavidin-
horse radish peroxidase (1:15,000; Jackson Immunoresearch). Bands were
detected using enhanced chemiluminescence (ECL) and exposure to light-
sensitive film. As a control for equal loading of the cell lysates, immunoblots
for actin (sc-1615, Santa Cruz) were also performed.
MMP cleavage of RANKL and identification of cleavage site
Total RNA was isolated from murine mammary glands and RANKL cDNA
was generated using standard RT protocols. Full-length RANKL was ampli-
fied using the following primers: sense, 5#-CGC-GCT-CGA-GAT-GCG-CCG
GGC-CAG-3#, and anti-sense, 3#-GCG-CAA-GCT-TAA-GTT-CCA-CGA-
AAT-GAG-TCT-CAG-5#. The PCR conditions were as follows: 1 cycle of
95°C for 5 min, and 35 cycles of 95°C for 60 s, 60°C for 60 s, and 72°C for
4 min, to give an expected product of approximately 975 base pairs. RANKL
cDNA was then inserted into the protein expression vector pcDNA3.1/Zeo-
(Invitrogen Life Technologies). Using 35S labeled methionine, the RANKL
protein was translated in vitro using a commercially available kit (TnT T7
transcription/translation system, Promega) according to the manufacturer’s
instructions. Subsequent full-length RANKL protein was incubated for 6 hr
at 37°C with either MMP-3, MMP-7, MMP-2, MMP-9, or MMP-13 (Onco-
gene/Calbiochem) in the following reactions: 10 µl of full-length RANKL in vitro
translated product with 100 ng of each active MMP to be tested, and
brought to a final volume in 50 µl of buffer (0.15 M NaCl, 50 mM Tris-HCl
[pH 7.6], 5 mM CaCl2). Reactions were stopped with the addition of 10 mM
EDTA. For analysis of cleavage products, samples were resolved using a
15% SDS-PAGE gel. The gels were then dried and imaged with autoradiog-
raphy film. For MMP inhibition, BB-94 (British Biotech) at a final concentra-
tion of 5 µM was added to the reactions prior to incubation. The functional
activity of the MMPs was confirmed by adding 100 ng of enzyme to 0.8 µg
of DQ-gelatin substrate (Molecular Probes) in a final volume of 80 µl of
reaction buffer (50 mM Tricine [pH 7.4], 0.2 M NaCl, 10 mM CaCl2, 50 µM
ZnSO4 and 0.005% Brij 35) and assaying for the increase in fluorescence
(Ex 485 nm; Em 530 nm) over 150 min. EDTA (10 mM) was also added to
separate reactions to demonstrate that the increases in fluorescence were
due to MMP activity. For identification of the RANKL cleavage site, 2 µg of
recombinant RANKL (R&D Systems) was incubated overnight at 37°C with
100 ng of active of MMP-7. The MMP cleavage products were resolved
using 15% SDS-PAGE gels, transferred to polyvinyl difluoride (PVDF) mem-
branes, and stained with 0.025% Coomassie in 40% MeOH. The 24 kDaA
band was excised from the PVDF and submitted for N-terminal amino acid
sequencing to Proseq Inc.
Cell culture and transient transfection assays
OCLBCL-XL TAG cells were a kind gift from Dr. David G. Roodman, and
Cos-7 cells were obtained from the ATCC. Conditioned media was obtained
by culturing the OCLBCL-XL TAG cells for 48 hr in serum free media. For
transient transfections, Cos-7 cells were transfected with 1 µg of the
RANKL expression vector using Superfect reagent (Qiagen) as per manu-
facturer’s instructions. For cleavage of RANKL by MMPs, Cos-7 cells were
incubated in serum-free media containing active MMP-3 or MMP-7 at aCANCER CELL : MAY 2005concentration of 100 ng/ml for 24 hr. For MMP inhibition studies, the broad-
spectrum MMP inhibitor BB-94 was added to the cells at a concentration
of 5 µM daily. After incubation, conditioned media was removed, and the
cells were lysed using a membrane lysis buffer (0.5% NP-40, 50 mM Tris-
HCl [pH 7.5], 100 mM NaCl) with protease and phosphatase inhibitors.
Equal amounts of protein from the cell lysates and conditioned media were
loaded for immunoblotting.
Osteoclast activity and functional assays
Using standard procedures, monocytes were collected from human periph-
eral blood, and 5 × 105 cells were incubated in either 8-well chamber slides
or 96-well plates containing dentin discs (Alpco) for one hour. Adherent cells
were washed extensively, then treated with α-MEM media containing 10%
FBS alone (control) or containing RANKL at 50 ng/ml or MMP-7-cleaved
RANKL at 50 ng/ml. Cells were treated every 2 days for 3 weeks and subse-
quently analyzed for osteoclast formation. For the osteoclast activity assay,
the numbers of osteoclasts in three random fields at 10× magnification from
multiple replicate experiments were photographed, and fully mature multi-
nucleated TRAP-positive or actin ring-positive osteoclasts were counted in
each test and control experiment. For osteoclast functionality assays, den-
tin discs were removed from culture and sonicated for 2 min in 5 ml of
0.25 M ammonium hydroxide to remove cells. The discs were then stained
for 5 min (0.05% toluidine blue in 40% MeOH) and air-dried. The total num-
ber of pits formed per disc was counted using reflective light microscopy.
Statistical analysis
For in vivo data, statistical analysis was performed using the Kruskal-Wallis
and Bonferroni/Dunn multiple comparison tests. In vitro data are presented
as mean ± standard deviation (SD). In vitro, statistical significance was ana-
lyzed using a two-tailed student’s t test. A value of p < 0.05 was consid-
ered significant.
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